LP
ISEE

Lexington Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Lexington Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-153,977
Closed -$785K – 4
2020
Q2 		$785K Buy
+153,977
New +$642K 0.61% 3

Other funds holding ISEE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Lexington Partners's ISEE Position: Q3 2020 in Review

Lexington Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2020, closing a stake of 153,977 shares — an estimated $785K sold.

Lexington Partners first reported a position in ISEE in Q2 2020 and held it in 1 quarter. The position peaked at $785K in Q2 2020. 101 funds tracked by Wall St. Rank hold ISEE as of Q3 2020.

  • Lexington Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Lexington Partners sold 153,977 IVERIC bio, Inc. Common Stock shares in Q3 2020, an estimated $785K.
  • Lexington Partners first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Lexington Partners's IVERIC bio, Inc. Common Stock position peaked at $785K in Q2 2020.
  • 101 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2020.

Based on Lexington Partners's 13F filing for Q3 2020, filed 13 Nov 2020.